Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 17 Jul 2015 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
- 17 Jul 2015 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
- 17 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History